A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.

开始日期2024-12-12

申办/合作机构

SWOG

[+1]

NCT06632977 / Not yet recruiting临床2期IIT

PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type of anti-androgen. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to tumor cells which damages and kills these cells. Assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing

开始日期2024-10-13

申办/合作机构

Alliance for Clinical Trials in Oncology

[+1]

NCT06353386 / Recruiting临床1/2期

MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study.

开始日期2024-05-20

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

100 项与卡巴他赛相关的临床结果

登录后查看更多信息

100 项与卡巴他赛相关的转化医学

登录后查看更多信息

100 项与卡巴他赛相关的专利（医药）

登录后查看更多信息

1,217

项与卡巴他赛相关的文献（医药）

2025-02-01·Clinical Genitourinary Cancer

The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study

Article

作者: Samantas, Epaminontas ; Fountzilas, George ; Petrakis, Georgios ; Efstathiou, Eleni ; Visvikis, Anastasios ; Tsiatas, Marinos ; Fountzilas, Elena ; Kanellis, Georgios ; Goussia, Anna ; Liontos, Michalis ; Papadopoulou, Kyriaki ; Korfiatis, Nikolaos

BACKGROUND:

Cabazitaxel is an effective treatment in metastatic castration-resistant prostate cancer (mCRPC) patients previously exposed to docetaxel and novel hormonal treatments. Understanding the molecular biology of mCRPC disease and taking into account the several approved treatment options, biomarkers are needed to guide decision making including cabazitaxel treatment.

METHODS:

Cababone was a phase II translational study that attempted to identify predictors of cabazitaxel efficacy. mCRPC with documented bone metastases were enrolled prospectively and treated with cabazitaxel 25mg/m² every 3 weeks. Prostate cancer biopsies, bone marrow aspirates and blood samples were collected for translational research.

RESULTS:

Sixty patients were enrolled and 59 received treatment according to protocol. Six-month progression free survival (PFS) rate was 47% (95% CI: 33% - 59%) and 12-month Overall Survival (OS) rate was 70% (95% CI: 56% - 80%). Patients with reactive hematopoiesis had improved PFS and OS with cabazitaxel treatment. Mutations in HRR genes were detected in 7 patients.

CONCLUSIONS:

No differences in cabazitaxel efficacy were noted according to mutational status of HRR genes analyzed. No new safety issues were detected. In conclusion, CabaBone confirmed efficacy of cabazitaxel in mCRPC patients including the subgroup of patients with HRR mutations. Reactive hematopoiesis in bone marrow biopsies was related to improved survival warranting further investigation of bone biomarkers as predictors of cabazitaxel efficacy.

2024-12-31·Cancer biology & therapy

Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes

Article

作者: Cecener, Gulsah ; Eryilmaz, Isil Ezgi ; Egeli, Unal

Redox adaptation causes poor prognosis by adapting cancer cells to excessive oxidative stress. Previously, we introduced an oxidative stress-resistant metastatic prostate cancer (mPC) model (LNCaP-HPR) that redox adaptation reduced the effect of Cabazitaxel (Cab), the last taxane-derivative for metastatic castration-resistant PC (mCRPC). Whereas, we investigated for the first time whether there is an association between the altered apoptotic effect and pro-oxidant efficacy of Cab on the redox adaptation in PC cells with different phenotypes, including LNCaP mPC, LNCaP-HPR, C4-2 mCRPC, and RWPE-1 cells. Cab was shown pro-oxidant efficacy proportionally with the apoptotic effect, more prominent in the less aggressive LNCaP cells, by increasing the endogenous ROS, mitochondrial damage, and inhibiting nuclear ROS scavengers, p-Nrf2 and HIF-1α. However, the pro-oxidant and apoptotic effect was lower in the LNCaP-HPR and C4-2 cells, indicating that the drug sensitivity of the cells adapted to survive with more ROS was reduced via altered regulation of redox adaptation. Additionally, unlike LNCaP, Cab caused an increase in the p-NF-κB activation, suggesting that the p-NF-κB might accompany maintaining survival with the increased ROS in the aggressive PC cells. Moreover, the cytotoxic and apoptotic effects of Cab were less on RWPE-1 cells compared to LNCaP but were closer to those on the more aggressive LNCaP-HPR and C4-2 cells, except for the changing pro-oxidant effect of Cab. Consequently, this study indicates the variable pro-oxidant effects of Cab on redox-sensitive proteins, which could be a target for improving Cab's apoptotic effect more in aggressive PC cells.

2024-12-01·Clinical Genitourinary Cancer

Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel – A multicentric Study From Portugal

Article

作者: Augusto, Isabel ; Custódio, Sandra ; Febra, Joana ; Rodrigues, Filipe ; Silva, Carlos ; Portela, Catarina ; Braga, Isaac ; Miranda, André ; Pacheco-Figueiredo, Luís ; Teves, Frederico ; Leão, Ricardo ; Gago, Patrícia ; Liu, Patrícia ; Dias, Jorge ; Oliveira, Jorge ; Botelho, Francisco

INTRODUCTION AND OBJECTIVES:

New drugs for metastatic castrate resistant prostate cancer (mCRPC) were approved, first in the pos-docetaxel and then in the pre-docetaxel setting. We aim to assess the real daily practice benefit of abiraterone (Abi), enzalutamide (Enz) and cabazitaxel (Cab) in patients with mCRPC, compare it with RCT results and compare Abi vs Enz.

MATERIALS AND METHODS:

We retrospectively collected the data of all consecutive mCRPC patients treated with Abi, Enz or Cab in the six major oncological hospitals in the north of Portugal until December 2020.

RESULTS:

A total of 470 treatments pre-docetaxel (163 Abi and 307 Enz) and 373 pos-docetaxel (160 Abi, 148 Enz and 59 Cab) were included, with median follow-up time of 35 months. Mean age was 73.1, 84.4% had ECOG status < 2, ISUP grade was ≥ 4 in 59% and 28.0% had oligometastatic disease. In first line, for Abi and for Enz respectively, the proportion of patients with PSA reduction > 50% was 64.4% and 80.4% (P < .001), the mean duration of treatment (DT) was 10 and 14 months (P = .037) and the median overall survival (OS) was 25 months and 30 months (P = .17). In second line the results for Abi, Enz and Cab were respectively: proportion of patients with PSA reduction > 50% was 40.4%, 57.4% and 24.6% (p for Abi vs Enz=0.004); DT was 7, 8, and 3 months (p for Abi vs Enz = 0.27); OS was 17, 22 and 10 months (p for Abi vs. Enz = 0,07).

CONCLUSION:

These drugs have good efficacy in real-world evidence, similar to those reported in randomized clinical trials, with the expected exception of lower OS due to the inclusion of a broader sample of patients. Our results add to the evidence that Enz might have better efficacy in this setting compared with Abi.

项与卡巴他赛相关的新闻（医药）

2024-11-25

·ioncology

朱刚教授：更新患者康复理念，个体化治疗改善前列腺癌患者多阶段获益丨2024 CCHIO

点击上方蓝字关注我们编者按：随着经济发展、生活方式和环境改变，我国前列腺癌发病率呈明显上升趋势。筛查前列腺癌高风险人群，并根据患者特征进行精准治疗及康复支持，对于提高患者治愈率并改善生活质量至关重要。在近期举行的2024年中国整合肿瘤学大会（CCHIO）上，中国抗癌协会泌尿生殖肿瘤整合康复专业委员会主任委员、北京和睦家医院大外科及泌尿外科主任报告了《前列腺癌的个体化治疗》的精彩内容，会后本刊特邀朱刚教授进行深入分享。 01 《肿瘤瞭望-泌尿时讯》当前的前列腺癌治疗提倡个体化。结合临床经验，如何看待基因检测和液体活检等技术对于精准治疗和个体化治疗的价值？朱刚教授：首先，十分感谢肿瘤瞭望-泌尿时讯频道进行的采访。我来自北京和睦家医院，并且担任中国抗癌协会泌尿生殖肿瘤整合康复专业委员会主任委员。今天，我想借此机会与大家探讨前列腺癌的个体化治疗这一话题。在肿瘤治疗领域，我们确实经历了一段发展历程。对于外科医生及患者而言，过去可能认为只要能够成功完成手术并切除肿瘤就已经足够满意。然而，随着技术的进步、理论的发展以及医疗设备的更新换代，我们现在正处于一个新的时代——不仅要求通过手术“彻底治愈”疾病，同时也要尽可能地保留患者的正常生理功能；就前列腺癌手术而言，尿控功能和男性勃起功能是我们重点关注的内容之一。关于之前提到的基因检测和液体活检技术，在前列腺癌诊断和治疗中扮演着越来越重要的角色。尤其是对于那些具有家族史的患者来说，进行BRCA1/2等特定基因突变的筛查显得尤为重要。目前研究发现，在有家族遗传背景的前列腺癌病例中，特别是BRCA2基因突变较为常见。因此，对于存在相关家族史的人群，我们强烈建议其男性成员考虑接受BRCA1/2基因检测，这对于提高早期发现率以及采取有效的预防措施具有重要意义。至于液体活检，目前仍在进行研究，临床应用仍需要进一步验证。 02 《肿瘤瞭望-泌尿时讯》对于根治性前列腺切除术患者，如何根据不同患者选择个体化的整合康复计划？朱刚教授：在肿瘤治疗领域，康复理念的应用正逐渐受到重视。以往，康复主要应用于骨科手术后的恢复过程；而现在我们认识到，在整个肿瘤治疗流程中，包括从诊断、治疗到恢复的各个阶段，都应当融入康复的理念。康复涉及多个方面，如心理康复、营养支持、运动医学以及中医等多学科的综合参与。特别是在前列腺癌的治疗过程中，从初次确诊到完成治疗再到后期恢复，患者及其家属可能会经历的心理压力和焦虑情绪，因此提供及时有效的心理辅导和支持变得尤为重要。此外，虽然医生对手术已经习以为常；但对于即将接受手术的患者来说，了解手术目的、可能遇到的并发症以及术后尿控功能和勃起功能等预期结果同样至关重要，这有助于缓解他们的不安感并促进医患之间的良好沟通。鉴于当前医疗机构中医生工作繁忙等现状，很难保证每位患者都能获得充足的咨询时间。为此，我们在中国整合肿瘤学大会上发布了《中国抗癌协会泌尿男生殖系肿瘤患教手册》，该手册涵盖了包括前列腺癌、肾癌、膀胱癌等在内的九种常见泌尿系统恶性肿瘤，基于循证医学原则以及加速康复外科（ERAS）理念，提供了多项信息。通过阅读这本手册，患者不仅能够加深对自己所患疾病的理解，还能学习如何更好地配合医护人员的工作，提高治疗效果。同时建议患者将自己关心的问题记录下来，在与医生交流时提出，以便于更高效地解决问题。就围术期的患者康复而言，我们提倡采用加速康复外科的理念来优化患者的治疗方案。例如，在饮食安排上，传统做法要求患者在术前长时间禁食（通常前一天晚上开始禁食，甚至因为手术排期，患者需要等到第二天下午）；但现代观点认为，除非有特殊禁忌症存在，否则可以在手术前6小时适量摄入易于消化的食物（如淀粉类食物等）；而在术前2小时则允许饮用清水甚至含糖饮料。这些调整旨在减少不必要的饥饿感，减轻身体负担。至于性功能恢复方面，使用低剂量PDE-5抑制剂已被证实可以帮助部分男性患者更快地恢复正常的勃起能力。而对于尿失禁问题，除了依赖于高水平的手术技巧外，还可以通过实施盆底肌肉锻炼来进行辅助治疗——具体方法是每天3次，每次重复10遍提肛动作，每次持续1分钟然后休息3~4分钟。研究表明，坚持这样的训练计划有助于加快尿控功能的恢复速度。 03 《肿瘤瞭望-泌尿时讯》在临床实践中，对于mHSPC患者选择个体化的治疗方案，您有哪些建议？朱刚教授：针对转移性激素敏感性前列腺癌（mHSPC），国际上已建立了一套较为标准化的治疗方案。对于此类患者，通常采用标准雄激素剥夺疗法作为基础治疗手段，这包括但不限于药物去势（如注射促黄体生成素释放激素类似物）或手术去势（双侧睾丸切除术），并结合抗雄激素药物治疗，这些综合治疗方案已被广泛认可。此外，在某些情况下，化疗也是一种可选方案，特别是多西他赛等药物的应用，在控制疾病进展方面展现出了一定的疗效。然而需要注意的是，由于每位患者的具体情况不同，尤其是肿瘤转移程度各异，因此最终效果可能存在差异。基于此，强烈建议患者寻求泌尿外科或泌尿系统肿瘤医生的意见，以获得最适合个人状况的最佳治疗计划。同时值得注意的是，长期使用上述治疗方法可能会对骨骼健康造成不利影响，增加病理性骨折的风险。为预防此类并发症的发生，推荐接受相关治疗的患者定期补充钙质及维生素D，具体操作简便易行——每日一片复合制剂即可有效降低骨相关事件的发生几率。因此，请广大患者朋友务必重视这一环节，确保自身骨骼强度维持在良好状态。 04 《肿瘤瞭望-泌尿时讯》对于疾病的终末阶段的mCRPC患者，如何选择最佳治疗策略，以改善患者症状同时延缓疾病进展？朱刚教授：转移性去势抵抗性前列腺癌（mCRPC）是指尽管已通过外科或药物方法实现去势，使体内睾酮水平降至极低（通常低于50 ng/dL），但肿瘤仍然持续进展的一种疾病状态。这种情况下的肿瘤对传统去势疗法不再敏感，故也称为转移性激素抵抗性前列腺癌。需要特别强调的是，在面对mCRPC时，不应停止去势治疗。所有进一步的治疗措施，包括新型抗雄激素药物的应用以及化疗等，均建立在持续去势治疗的基础上。因此，患者必须继续接受原有的去势治疗，无论是注射还是口服形式。针对mCRPC，近年来出现了多种创新疗法。例如，达罗他胺和阿帕他胺等新一代抗雄激素药物，被证明能有效提高患者生存率并延缓病情进展。此外，曾经认为对前列腺癌无效的化疗，现在也有研究表明某些特定药物如多西他赛和卡巴他赛能够显著改善预后，不仅有助于控制肿瘤生长，还能缓解由疾病引起的症状。对于出现骨转移导致严重疼痛的患者，使用钙补充剂及其他保护骨骼健康的药品是常规方案之一。另外，放射性同位素治疗，比如镥177药物，在国际上的研究显示其可以有效减轻骨痛并减慢疾病进程。当疾病进入晚期阶段且难以治愈时，关注患者的生活质量变得尤为重要。此时，提供专业的缓和医疗至关重要，旨在确保患者能够在尊重个人意愿的前提下度过最后时光，尽可能减少身体不适感，增强生命体验的质量。总之，无论处于哪个治疗阶段，维护患者的尊严、减轻痛苦及提供全面的支持都是医疗工作中不可或缺的一部分。朱刚教授和睦家医疗北京区副医疗总监，大外科主任，泌尿外科主任英国伦敦大学国王学院医学博士国之名医、中国泌尿肿瘤特别贡献奖获得者中国抗癌协会（CACA）理事、国际交流工作委员会委员中国抗癌协会泌尿生殖肿瘤整合康复专业委员会（CACA-GUHR）主任委员中国抗癌协会泌尿肿瘤专业委员会（CACA-UO）副主任委员亚洲泌尿外科机器人学会（ARUS）科学委员会主席中华医学会泌尿外科学分会（CUA）肿瘤及机器人学组委员中国临床肿瘤学会（CSCO）前列腺癌专家委员会常委中国良性前列腺增生、前列腺癌、膀胱癌指南编委 EAU-ICUD肾癌、前列腺癌指南编委 NCCN前列腺癌、肾癌、膀胱癌亚洲共识编委 Robotic Urologic Surgery分篇主编发表专业论文107篇，其中SCI文章22篇。主编及参编专著22本，其中英文专著8本。从事泌尿外科临床工作34年。在国内外接受过良好临床理论与技能培训。专业方向为泌尿外科肿瘤学，前列腺疾病，微创外科治疗及内镜手术和其他泌尿外科常规诊治。擅长机器人手术、标准腹腔镜手术、单孔腹腔镜及内镜手术。（来源：《肿瘤瞭望-泌尿时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2024-11-05

·药事纵横

紫杉烷类谁会是下一个口服溶液？

2024年9月19日，中国食品药品监督管理局（NMPA）批准了由上海海和药物研究开发股份有限公司与韩国大化制药股份有限公司合作研发的紫杉醇口服溶液，主要用于一线含氟尿嘧啶类方案治疗期间或治疗后出现疾病进展的晚期胃癌患者的治疗。紫杉醇口服溶液的成功上市，不仅是对现有治疗方案的补充和完善，更是对新药研发方向的积极探索。作为全球首款，中国首个获批上市紫杉烷类口服药物里程碑式的一个节点，无论是对患者还是对整个医药市场都有其诸多的意义！一：紫杉烷类药物的简介紫杉烷类是从植物中分离得到的抗肿瘤活性成分，并对已分离的活性成分进行结构修饰，合成的一系列衍生物，对大多数癌症其均有一定的活性。紫杉烷类药物具有相同的抗癌机制：通过稳定微管蛋白，促进其聚合，抑制微管解聚（能够干扰肿瘤细胞微管的形成,导致微管“束”排列异常），从而阻止细胞的有丝分裂，达到抗癌效果。紫杉醇和多西他赛（多西紫杉醇）属于第一代紫杉烷类药物，多西他赛是在紫杉醇的结构基础上稍加改良，在疗效，用法和安全性方面相比紫杉醇有所不同，不同点在于其水溶性和微管结合部位的亲和力更高，具有较高的抗癌活性。卡巴他赛属于二代紫杉烷类抗癌药，是在紫杉醇和多西他赛结构及已存在问题的基础上进一步的“升级改良”。从而对第一代紫杉烷耐药的癌细胞有一定的活性。有文献及临床数据显示，卡巴他赛可作为紫杉醇类药物经治疗的HER2阴性转移性乳腺癌患者的二线治疗选择，卡巴他赛对于转移性去势抵抗性前列腺癌（mCRPC，指经过初次持续雄激素剥夺治疗后疾病依然进展并向身体其它组织转移的前列腺癌）有明显的治疗作用，即用一线多西他赛和/或新型内分泌治疗失败后的mCRPC，可显著改善mCRPC患者的生活质量。 CDE官网显示以紫杉醇、多西他赛和卡巴他赛为原料的剂型主要以注射剂为主，给药方式均为注射。紫杉烷类药物在BCS分类系统里属于Ⅳ类，原料药自身的属性特点导致了其生物利用度差。针对于剂型方面的改良，以紫杉烷类紫杉醇为例从注射液到脂质体再到注射用紫杉醇（白蛋白结合型），剂型方面的改良已很大程度的改善了原料药和辅料带来的缺点，但给药方式始终停留在注射，未在给药方式上有大的突破。传统的注射给药方式在增加了临床工作者给药难度和风险的同时患者的化疗成本及痛苦也在增加。紫杉烷类医药市场急需一款在保证抗癌疗效的同时又能改变给药方式的剂型出现。二：紫杉醇口服溶液的简介紫杉醇口服溶液是上海海和药物研究开发股份有限公司携手韩国大化制药共同研制的，利用脂质自乳化药物递送技术（Self- Emulsifying Drug Delivery System,SEDDS）将药物包裹在脂质颗粒中，采用的特殊脂质载体具有自乳化特性，能够在水和油的混合物中自发形成稳定的乳液，这种乳液能够在胃部的酸性环境中保持稳定，同时在肠道pH值的变化下而自发解散，从而使紫杉醇得以被肠道吸收，这种通过口服的形式给药，显著提高了药物的生物利用度和患者的用药便利性。针对于紫杉烷类药物剂型先前的给药方式均以注射为主，显然紫杉醇口服溶液的上市具有里程碑式的意义，它的出现不仅表明紫杉烷类药物在给药方式上的一个重大突破，也对其它紫杉烷类乃至其它癌症的治疗探索提供了新的思路和新的方法，具有借鉴式的意义！现就其紫杉醇口服溶液药用机理的设计原理简单分析，以便为其它紫杉烷类药物的开发提供些许的思路和启发。在《详解全球首款紫杉醇口服溶液设计原理》一文中提到了紫杉醇口服溶液的成分为紫杉醇（Paclitaxel），单油酸甘油脂（Monoolein），三辛酸甘油脂（Tricaprylin），吐温80（Tween80）,其含量的占比分别为1％、55％、27.5％和16.5％。实验表明辅料甘油酯的加入是因为它对紫杉醇有很好的溶解度，吐温80的加入能够显著增加紫杉醇口服后的体内暴露量，单油酸甘油酯是决定其给药方式改变的关键性辅料（高效的粘膜粘附性可以使其粘附在肠道的黏液层上，是药物吸收发生的有效部位，提高了该制剂在肠道内的滞留时间和吸收效率，对口服生物利用度有着积极的影响），三者的共同作用提高了其生物利用度，降低了毒副作用，为癌症患者提供了新的治疗选择。三：展望早在2013年国家卫生计生委发布的合理用药十大核心信息中就明确指出并强调用药原则为：能口服不肌注，能肌注不输液，在保证临床疗效的前提下，该用药原则能够最大程度减轻用药过程中的风险，更好的服务于患者，口服的给药途径无论对于医务工作人员还是患者来说无疑是最便捷、安全、舒适的给药方式。所以，针对于原料药剂型的设计从给药途径方面考虑，在保证临床疗效的前提下首先考虑的给药途径为口服。紫杉烷类传统的制剂形式采取的给药方式均为静脉给药，需经配制后在医院经静脉滴注给药，患者需频繁回返医院进行治疗，且注射部位会有不良反应。紫杉醇口服溶液作为紫杉烷类全球首款新的给药方式获批上市其优势及意义体现在以下几点：①提高患者用药的便利性，减轻用药痛苦。②通过新的药物递送技术降低了现有制剂的不良反应率。③以紫杉醇口服溶液为基点，探索研究其辅料运用在口服制剂领域的机制加快紫杉烷类其它药物口服途径的一个研发。针对上面第三点个人认为搞清楚弄明白其内辅料发挥作用的机理，以便于指导一个原料药目前市场上不存在的剂型用于口服的给药途径意义是非常大的，它需要相关医药领域多个部门的合作！探索！创新!现针对这方面谈谈自己的理解和想法，在这里重申下紫杉醇口服溶液三种辅料在目前的研究和认知范围内的一个作用。单油酸甘油酯：高生物粘附性以及潜在的口服吸收促进作用，甘油三脂：对紫杉醇良好的溶解度，吐温80：能够显著增加紫杉醇口服后的体内暴露量。紫杉醇口服给药造成生物利用度低的原因是多种因素叠加而成的，主要因素包括药物被相关酶系代谢以及肠道上皮细胞和肝脏中存在的外排系统等……这些机制的共同作用造成了口服给药后胃肠道吸收不佳，口服生物利用度低。紫杉醇口服溶液能够显著提升生物利用度从以上三种辅料来看起主要作用的为单油酸甘油酯，已有文献报道之所以能够增加生物利用度是因为其有高生物粘附性，有可能在口服给药中能够增强小分子甚至蛋白质通过上皮细胞的吸收，但其吸收的机制尚不清楚，在体外研究表明，其之所以能够口服是其可以通过抑制P-糖蛋白来增强药物的细胞吸收等等……尚未对其有明确的定论。有许多值得药物研发人员去探索的地方，我想在未来经过一代又一代医药研发人员的不懈努力，将实则一些偶然性的因素“刨根问底”，在此基础上开发运用到其它紫杉烷类药物，我相信科研人员在大量探索其辅料作用机理研究的基础上,下个多西他赛和/或卡巴他赛口服溶液的出现将指日可待！四：总结文章的一开始简单为大家介绍了紫杉烷类药物的作用机制及各个衍生物的特点，以及目前紫杉烷类药物在市场上运用的剂型，紧接着为大家介绍了紫杉醇口服溶液的成分组成及各个组分所起到的大致作用，使大家对紫杉醇口服溶液有了一定的了解，接下来重点给大家谈了笔者个人对下个紫衫烷类口服溶液的出现谈了下自己的一些想法和期许。正所谓：“拨云见日终有时,守得云开见月明”，有了紫杉醇口服溶液，多西他赛和卡巴他赛口服溶液还会远吗？给时间以时间，让我们共同期待它们的到来，更好的服务于临床患者，减轻患者的痛苦，给他们多一个用药选择！路虽远行则将至，事虽难做则必成！五：参考文献【1】详解全球首款紫杉醇口服溶液处方设计原理【2】紫杉类耐药，HER2阴性转移性乳腺癌，卡巴他赛二线治疗安全有效【3】贝海生物第三代紫杉烷类衍生物新药获批临床【4】紫杉醇口服溶液获批上市：晚期胃癌治疗的新里程碑【5】Kang YK, Ryu MH, Park SH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018 May 1;29(5):1220-1226. 药事纵横征稿启事

上市批准

2024-10-10

·PRNewswire

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Metastatic Castration-Resistant Prostate Cancer (mCRPC) refers to prostate cancer that has spread (metastasized) to other parts of the body and continues to progress despite treatments that lower testosterone levels (androgen deprivation therapy or ADT) major pharmaceutical companies are heavily investing in research and development of new treatments, including immunotherapy (e.g., sipuleucel-T) and targeted therapies, which are seen as the next frontier in treating mCRPC. The use of precision medicine to identify genetic profiles in patients has further expanded the potential for targeted treatment. LAS VEGAS , Oct. 10, 2024 /PRNewswire/ -- DelveInsight's ' Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline mCRPC therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the mCRPC pipeline domain. Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report DelveInsight's mCRPC pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for mCRPC treatment. Key mCRPC companies such as Regeneron Pharmaceuticals, AstraZeneca, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Forma Therapeutics, Inc., HALDA THERAPEUTICS INC., Tavanta Therapeutics, Lantheus, Pfizer, AB Science, Syntrix Pharmaceuticals, Exelixis, Laekna Therapeutics Shanghai Co. Ltd., Cardiff Oncology, Ipsen, Norroy Bioscience, Astellas Pharma, Novartis, Johnson & Johnson, Tempest Therapeutics, and others are evaluating new mCRPC drugs to improve the treatment landscape. Promising mCRPC pipeline therapies such as REGN 4336, Capivasertib, Deutenzalutamide, ZEN003694, Abemaciclib, Enfortumab vedotin, Talazoparib, I-131-1095, Pelgifatamab corixetan, AC176, HP518, FT-7051, HLD-0915, TAVT-45, PNT2002, Mevrometostat, Masitinib, SX-682, XL092, LAE001, Onvansertib, Tazemetostat, 177Lu-NYM032, PRL-02, 225 Actinium PSMA 617, ARX51, TPST-1120, and others are under different phases of mCRPC clinical trials. In October 2024, Curium announced that it had entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T. The two agents 177Lu-PSMA-I&T and 64Cu-PSMA-I&T target prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate cancer treatment and diagnostics. In July 2024, the US FDA granted fast-track designation to the prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical 225Ac-FL-020 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In July 2024, Merck and Orion Corporation announced the mutual exercise of option providing Merck global exclusive rights to Opevesostat, an investigational CYP11A1 inhibitor, for the treatment of Metastatic Castration-Resistant Prostate Cancer. In July 2024, the US FDA granted fast-track designation to the antibody-drug conjugate (ADC) BNT324/DB-1311 to potentially treat patients with unresectable advanced or metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed on or after standard systemic regimens. In July 2024, FutureChem announced that the FC-705 has received orphan drug designation from the Ministry of Food and Drug Safety (MFDS) for the treatment of prostate cancer. In June 2024, CAR T-Cell Therapy demonstrated promising results for mCRPC according to Phase I trial results. In January 2024, Lava Therapeutics announced that it has signed a clinical trial collaboration and supply agreement with Merck to evaluate its prostate cancer therapy LAVA-1207 as a combination treatment with MSD's Keytruda (pembrolizumab). In July 2024, Blue Earth Therapeutics announced the signing of a clinical research collaboration with University College London (UCL). The collaboration is centered on a Phase I/II trial designed to evaluate the safety, tolerability, radiation dosimetry, and antitumor activity of the 225Ac-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer who have previously responded to lutetium 177 (177Lu)-PSMA therapy. Request a sample and discover the recent advances in mCRPC treatment drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Report The mCRPC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mCRPC drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the mCRPC clinical trial landscape. Metastatic Castration-Resistant Prostate Cancer Overview Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer that continues to grow and spread despite hormone therapy aimed at lowering testosterone levels. The term "metastatic" refers to cancer spreading to other parts of the body, such as the bones, lymph nodes, or distant organs, while "castration-resistant" indicates that the cancer no longer responds to treatments that reduce testosterone, a key driver of prostate cancer growth. mCRPC is typically more aggressive and challenging to treat than earlier stages of prostate cancer. The causes of mCRPC stem from genetic and environmental factors. Genetic mutations in the androgen receptor pathway can make cancer cells less dependent on testosterone, allowing them to thrive even under hormone-suppressing treatments. Environmental factors like diet, lifestyle, and exposure to certain chemicals may also contribute to the development and progression of prostate cancer. Symptoms of mCRPC often include pain in bones, fatigue, difficulty urinating, weight loss, and general weakness. As the cancer spreads, it can impair the function of other organs, depending on the site of metastasis. Diagnosis of mCRPC usually involves a combination of tests, including prostate-specific antigen (PSA) blood tests, imaging studies like CT scans, MRIs, or bone scans, and sometimes biopsies to confirm the spread and resistance to treatment. Treatment options for mCRPC are more complex and may include newer hormonal therapies (e.g., abiraterone, enzalutamide), chemotherapy (docetaxel or cabazitaxel), immunotherapy (e.g., sipuleucel-T), or targeted therapies such as PARP inhibitors. Bone-targeting therapies, radiation, and palliative care can also be used to manage symptoms and improve the quality of life. Treatment is typically tailored to the individual based on the extent of the disease and the patient health. Find out more about mCRPC treatment drugs @ Drugs for Metastatic Castration-Resistant Prostate Cancer Treatment A snapshot of the mCRPC Pipeline Drugs mentioned in the report: Learn more about the emerging mCRPC pipeline therapies @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment The mCRPC pipeline report proffers an integral view of the mCRPC emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous Therapeutics Assessment By Molecule Type: Small molecule, Cell therapy, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Androgen receptor degradation enhancers, Antibody-dependent cell cytotoxicity, Proto-oncogene protein c-akt inhibitors, Androgen receptor antagonists, Bromodomain and extraterminal domain protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Ionizing radiation emitters, PPAR alpha antagonists. Key Metastatic Castration-Resistant Prostate Cancer Companies: Regeneron Pharmaceuticals, AstraZeneca, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Forma Therapeutics, Inc., HALDA THERAPEUTICS INC., Tavanta Therapeutics, Lantheus, Pfizer, AB Science, Syntrix Pharmaceuticals, Exelixis, Laekna Therapeutics Shanghai Co. Ltd., Cardiff Oncology, Ipsen, Norroy Bioscience, Astellas Pharma, Novartis, Johnson & Johnson, Tempest Therapeutics, and others. Key Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies: REGN 4336, Capivasertib, Deutenzalutamide, ZEN003694, Abemaciclib, Enfortumab vedotin, Talazoparib, I-131-1095, Pelgifatamab corixetan, AC176, HP518, FT-7051, HLD-0915, TAVT-45, PNT2002, Mevrometostat, Masitinib, SX-682, XL092, LAE001, Onvansertib, Tazemetostat, 177Lu-NYM032, PRL-02, 225 Actinium PSMA 617, ARX51, TPST-1120, and others. Dive deep into rich insights for new drugs for mCRPC treatment, visit @ Metastatic Castration-Resistant Prostate Cancer Drugs Table of Contents For further information on the mCRPC Cancer pipeline therapeutics, reach out @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs Related Reports Metastatic Castration-Resistant Prostate Cancer Market Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCRPC companies including AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, among others. Metastatic Prostate Cancer Market Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. Metastatic Castration-Sensitive Prostate Cancer Market Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. Metastatic Castration-Sensitive Prostate Cancer Pipeline Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key mCSPC companies, including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

快速通道免疫疗法临床1期临床结果

100 项与卡巴他赛相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09755 D10452	卡巴他赛	L01CD04	DB06772

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
前列腺癌	日本	Sanofi KK	2014-07-04
转移性去势抵抗性前列腺癌	美国	Sanofi-Aventis U.S. LLC	2010-06-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前列腺腺癌	临床3期	法国	Sanofi	2013-12-01
局限性前列腺癌	临床3期	法国	Sanofi	2013-12-01
尿路上皮癌	临床3期	英国	Sanofi	2013-01-01
去势抵抗性前列腺癌	临床3期	美国	Aventis Pharma	2011-05-05
去势抵抗性前列腺癌	临床3期	美国	赛诺菲（中国）投资有限公司	2011-05-05
去势抵抗性前列腺癌	临床3期	美国	Sanofi-Aventis Recherche et Développement SA	2011-05-05
去势抵抗性前列腺癌	临床3期	日本	Aventis Pharma	2011-05-05
去势抵抗性前列腺癌	临床3期	日本	Sanofi-Aventis Recherche et Développement SA	2011-05-05
去势抵抗性前列腺癌	临床3期	日本	赛诺菲（中国）投资有限公司	2011-05-05
去势抵抗性前列腺癌	临床3期	丹麦	Aventis Pharma	2011-05-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02218606 (CTgov)	临床2期	转移性去势抵抗性前列腺癌	81	prednisone 5 mg po BID+Abiraterone acetate 1000 mg po daily (Abiraterone Acetate 1000 mg po Daily + Prednisone 5 mg po BID)	憲遞繭夢壓鬱壓鬱廠壓(憲遞窪範遞憲醖醖醖鏇) = 醖網鏇範選築夢餘壓選範積鬱積糧築膚壓網繭 (選蓋築顧鹽襯範襯製艱, 簾淵醖淵願網觸廠夢繭 ~ 繭壓鏇繭獵齋壓艱憲膚) 更多	-	2024-12-10
				Cabazitaxel 25 mg/m2 IV+prednisone 5 mg po BID+Abiraterone acetate 1000 mg po daily (Cabazitaxel 25 mg/m2 IV + Abiraterone Acetate 1000 mg po Daily)	憲遞繭夢壓鬱壓鬱廠壓(憲遞窪範遞憲醖醖醖鏇) = 繭網製憲簾淵壓製憲積範積鬱積糧築膚壓網繭 (選蓋築顧鹽襯範襯製艱, 鹽顧糧簾構範願簾衊鏇 ~ 鏇鹽範艱艱網壓製鹹鹹) 更多
NCT02202772 (ESMO2024) 人工标引	临床2期	非肌层浸润性膀胱尿路上皮癌	33	cabazitaxell cabazitaxelcisplatinbine, and cisplatin (CGC)	簾繭齋夢憲製膚獵壓簾(餘獵壓憲網網憲獵窪鏇) = 鹽鑰築範衊齋窪遞範憲夢網顧網繭製遞築網醖 (願窪構遞餘鬱選選鹽窪 ) 更多	积极	2024-09-15
CABASTY (ESMO2024)	N/A	转移性去势抵抗性前列腺癌	194	Triweekly 25mg/m2 cabazitaxel	選鹽衊鹽憲網選壓願簾(淵襯壓膚選鏇獵觸遞糧) = 鬱選網鹽夢顧壓積廠鏇鹽構蓋窪簾鑰壓構餘壓 (構願簾繭憲窪壓艱築蓋, 17.4 ~ 29.8)	积极	2024-09-15
				Biweekly 16mg/m2 cabazitaxel	選鹽衊鹽憲網選壓願簾(淵襯壓膚選鏇獵觸遞糧) = 餘鬱鏇膚廠繭壓夢淵鬱鹽構蓋窪簾鑰壓構餘壓 (構願簾繭憲窪壓艱築蓋 )
NCT02903160 (PRINT, CTgov)	临床2期	去势抵抗性前列腺癌	40	Radium-223 dichloride+Enzalutamide+Cabazitaxel+Carboplatin+Prednisone+Abiraterone acetate	獵淵淵鏇齋窪選鹽鏇積(憲築願觸鹹築網廠衊築) = 鏇觸夢蓋襯遞鹹糧鹹鏇廠醖願廠繭願齋簾構鏇 (網廠築夢膚淵鬱願淵獵, 糧鹹鹹憲衊遞艱淵壓鏇 ~ 夢襯衊鑰窪簾廠構獵糧) 更多	-	2024-02-07
EUCTR2017-003424-76-GB (ASCO_GI2024) 人工标引	临床1/2期	食管癌	15	DEP cabazitaxel 20 mg/m2	艱衊糧鹽鏇餘築鏇顧繭(觸憲齋積窪衊齋艱壓艱) = 憲醖繭艱憲衊衊窪憲觸餘願積衊壓窪鑰淵繭壓 (醖醖遞網築鹽鏇淵餘觸 ) 更多	积极	2024-01-18
				DEP cabazitaxel 20 mg/m2 (EG ADENOCA pts)	艱衊糧鹽鏇餘築鏇顧繭(觸憲齋積窪衊齋艱壓艱) = 製鹽觸鬱憲獵鹽積簾鬱餘願積衊壓窪鑰淵繭壓 (醖醖遞網築鹽鏇淵餘觸 ) 更多
NCT03295565 (OSTRICH, ESMO2023) 人工标引	临床2期	去势抵抗性前列腺癌	106	Cabazitaxel	鏇構顧遞壓膚鹽鑰簾鬱(築鏇選艱遞遞築鏇餘淵) = 夢憲製糧願鑰構繭積蓋積積衊醖襯蓋願築構築 (餘選選鏇獵網窪顧觸餘, 46.1 ~ 74.2) 更多	非优	2023-10-22
				Abiraterone or Enzalutamide	鏇構顧遞壓膚鹽鑰簾鬱(築鏇選艱遞遞築鏇餘淵) = 醖淵製襯衊鬱廠齋獵簾積積衊醖襯蓋願築構築 (餘選選鏇獵網窪顧觸餘, 52.9 ~ 79.7) 更多
NCT03903835 (ProBio, ESMO2023) 人工标引	临床3期	去势抵抗性前列腺癌一线	219	abiraterone or enzalutamide (Androgen receptor pathway inhibitors (ARPi))	遞網選製憲醖築顧鹹簾(蓋遞蓋蓋鏇繭醖範衊願) = 淵糧蓋鏇獵夢憲衊糧襯積窪醖窪選淵窪願醖鹹 (艱餘齋網蓋獵顧製製鬱, 9.8 ～ 13.1) 更多	积极	2023-10-22
				docetaxel or cabazitaxel (Taxanes)	鹽壓衊窪願範鏇壓網鬱(壓鹽築廠憲糧選構鏇艱) = 遞範蓋夢繭鑰艱淵選觸遞齋鬱壓網獵淵鹽簾鏇 (獵範鹽顧壓鏇繭鑰醖築, 18.4 ～ 23.0)
NCT04495179 (AARDVARC, CTgov)	临床2期	转移性去势抵抗性前列腺癌	30	AZD4635+Durvalumab (Arm A: AZD4635 + Durvalumab)	顧築襯艱鏇鹽醖襯獵醖(製獵遞廠醖衊夢淵衊鹹) = 鹽繭鹽遞獵鹹範構鑰膚鹹壓夢積餘構觸範齋積 (艱壓餘壓醖夢艱齋醖醖, 襯淵簾鹽製餘積選範願 ~ 醖餘遞遞蓋遞膚衊鏇憲) 更多	-	2023-08-09
				Cabazitaxel+AZD4635+Durvalumab (Arm B: AZD4635 + Durvalumab + Cabazitaxel)	鹽簾鑰醖鹽糧願膚醖遞(選範遞簾網製衊餘糧獵) = 網構鬱壓範鹹窪憲築齋憲鏇鏇簾鑰餘鏇襯範壓 (糧鏇顧願餘獵獵鏇廠網, 膚製糧製糧鏇構膚製願 ~ 鹹襯憲夢齋簾鏇襯蓋壓) 更多
NCT01616875 (ASCO_GU2023) 人工标引	临床2期	膀胱尿路上皮癌	26	Cabazitaxel + Cisplatin	淵蓋構窪積簾艱淵衊淵(積襯醖醖製餘構鹽襯繭) = 衊構糧範餘鏇襯簾醖範艱簾顧鑰鏇壓壓廠窪遞 (膚選憲築壓顧衊膚廠壓 ) 更多	积极	2023-02-21
				Cabazitaxel + Cisplatin (achieved ORR)	遞齋廠構顧願窪鹽築網(餘構膚衊鹽鹹獵壓遞遞) = 積衊膚顧繭鏇襯鹽鏇繭糧鏇製觸艱簾淵糧窪簾 (衊糧鹹積膚顧鏇觸製鏇 )
Pubmed 人工标引	临床2/3期	HER2 阴性乳腺癌一线 HER2 Negative	158	cabazitaxel	衊鏇簾構窪壓鑰壓鑰鑰(壓鹹蓋鬱衊鏇鹹廠夢選) = 鬱觸鏇製蓋糧衊窪夢鹽衊構糧鹹網鹹淵鬱淵醖 (壓夢糧衊顧餘膚憲壓夢 ) 更多	不佳	2022-09-24
				paclitaxel	衊鏇簾構窪壓鑰壓鑰鑰(壓鹹蓋鬱衊鏇鹹廠夢選) = 遞鹹壓觸網願鏇醖繭範衊構糧鹹網鹹淵鬱淵醖 (壓夢糧衊顧餘膚憲壓夢 ) 更多